MindMaze Therapeutics Holding SA (SIX: MMTX), today announced that the SwissNeuroRehab Consortium (www.swissneurorehab.ch) has enrolled its first patient in the High-Dose, High-Intensity (HDHI) neurorehabilitation study – Advancing At-Home Reimbursement Strategy in Europe. The study is a multicenter feasibility and implementation project evaluating whether HDHI neurorehabilitation can be delivered sustainably within a continuum-of-care framework. The study is powered by MindMaze’s precision neurotherapeutic platform (including MindMotionGO, Izar, and Companion). The study targets 300 minutes of active training per week, spanning a 4-6 week inpatient phase, an 8-12 week outpatient/home phase, and a follow-up at 15 months from inclusion. Recruitment is active at Lausanne University Hospital (CHUV), Institution de Lavigny, Rehaklinik Valens, Swiss…